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Interim analysis of the Reitan Catheter Pump (RCP) heart failure efficacy
study: RCP improves cardiovascular and renal function in acute
decompensated heart failure (ADHF) 
Thomas R Keeble1, Elliot J Smith1, Roger Hullin2, Markus Ferrari4, Oyvind Reitan3,
Fredrik Schersten3, Martin Rothman1, Sven- Erik Ricksten5
1London Chest Hospital, Bethnal Green, LONDON, United Kingdom; 2CHUV,
Lausanne, Switzerland; 3University Hospital, Lund, Sweden; 4University Hospital,
Jena, Germany; 5Sahlgrenska University Hospital, Gothenburg, Sweden
Background: The RCP is a 14 French collapsable percutaneous cardiovascular support
device positioned in the descending part of the thoracic aorta via the femoral artery. A
10 patient first in man study demonstrated device safety and significant improvement
in renal function among high risk PCI patients. We now report haemodynamic and
renal efficacy in patients with ADHF.
Methods: Prospective non randomised study seeking to recruit 20 patients with ADHF
with a need for inotropic or mechanical circulatory support with: i) EF < 30% ii)
Cardiac index(CI) < 2.2 L / min / m2 Outcome measures included: 1) Cardiac index
(CI) 2) Pulmonary Capillary Wedge Pressure (PCWP) 3) Urine output / serum
creatinine 4) Vascular / device complications 5) 30 day mortality
Results: INTERIM ANALYSIS (n=12) The mean age of the study group was 64 years,
with a mean baseline creatinine of 193 umol/L, eGFR 38 ml/min. The intended RCP
treatment period was 24 hours. During RCP treatment there was a significant mean
reduction of PCWP at 4 hours of 17% (25 to 21 mmHg p=0.04). Mean CI increased at
12 hours by 11%, though not reaching significance (1.78 to 1.96 L/min/m2 p=0.08).
RCP insertion prompted substantial diuresis. Urine output tripled over the first 12 hours
compared to baseline (55 ml/hr vs 213 ml/hr p=0.03). This was associated with
significantly improved renal function, a 28% reduction in serum creatinine at 12 hours
(193 to 151 umol/L p=0.003), and a increase in eGFR from 38 ml/min to 50 ml/min
(p=0.0007). 2 patients previously refused cardiac transplantation were reassessed and
successfully transplanted within 9 months of RCP treatment on the basis of
demonstrable renal reversibility. There were no vascular or device complications. There
were 2 deaths at 30 days, one from multi-organ failure and sepsis, and one from
intractable heart failure - neither were device related.
Conclusion: RCP support in ADHF patients was associated with improved
haemodynamics, and an improvement in renal function. The Reitan Catheter Pump
may have a role in providing percutaneous cardiovascular and renal support in the
acutely decompensated cardiac patient, and may have a role in suggesting renal
reversibility in potential cardiac transplant patients. Further data will be reported at
recruitment completion.
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Biomarkers to Predict Contrast Induced Nephropathy after Primary
Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial
Infarction: A HORIZONS-AMI substudy
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Background: Contrast-induced nephropathy (CIN) after percutaneous coronary
intervention (PCI) is associated with prolonged hospitalization and adverse clinical
outcomes. We sought to investigate whether biomarkers can be useful to predict the
occurrence of CIN after primary PCI for ST-segment elevation myocardial infarction
(STEMI).
Methods: A total of 26 inflammatory and thrombotic biomarkers were measured at
admission in 501 STEMI patients undergoing primary PCI enrolled in a formal
substudy of the HORIZONS-AMI trial, and analyzed at a central core laboratory. We
divided patients in tertiles based on biomarker levels and explored associations between
biomarkers and CIN defined as 1) a relative increase in serum creatinine of ≥25%, or
2) an absolute increase in serum creatinine of ≥0.5 mg/dL within 48 hours after primary
PCI.
Results: Information on CIN was available for 423 patients (84%). CIN defined as a
relative serum creatinine increase of ≥25% occurred in 60 patients (14.2%). High levels
of Brain Natriuretic Peptide (BNP), Pregnancy-Associated Plasma Protein A (PAPP-
A), von Willebrand factor (vWf), and heart-type fatty acid binding protein (hFABP)
were associated with this definition of CIN (Table 1). CIN defined as an absolute serum
creatinine increase of ≥0.5 mg/dl occurred in 15 patients (3.5%). Only Brain natriuretic
peptide (BNP) was associated with this definition of CIN (Table 1).
Conclusion: BNP, PAPP-A, vWF, and hFABP are potential biomarkers to predict CIN
in STEMI patients undergoing primary PCI. Larger prospective trials are warranted to
validate the utility of these biomarkers.
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Impact of Renal Impairment on Clinical and Angiographic Outcomes After
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Background: Renal impairment (RI) in patients undergoing percutaneous coronary
interventions (PCI) is associated with adverse prognosis. However, the impact of RI
on long-term clinical and angiographic outcomes among patients undergoing PCI with
the unrestricted use of drug-eluting stents (DES) is not well established.
Methods: Individual patient data were pooled for 5,011 patients from 3 all-comer trials
with the exclusive use of DES (SIRTAX - N=1,012, LEADERS - N=1,707,
RESOLUTE AC - N=2,292). Angiographic follow-up was available for 1,540 lesions.
Patients were stratified according to glomerular filtration rate (normal: ≥90 ml/min;
mild RI: 60-89 ml/min; moderate/severe RI: <60 ml/min). The primary endpoint was
the composite of cardiac death and myocardial infarction (MI). Angiographic endpoints
were in-stent late lumen loss (LL) and in-segment binary restenosis (BR).
Results: Through 2 years, patients with moderate/severe RI as compared to patients
with normal renal function had a higher risk of cardiac death or MI (adjusted OR=2.23,
95%CI 1.43-3.48, p<0.001), as well as cardiac death (adjusted OR=2.34, 95%CI 1.17-
4.67, p=0.02) and MI (adjusted OR=2.15, 95%CI 1.28-3.62, p<0.001). Patients with
mild RI as compared to patients with normal renal function had similar risk of cardiac
death or MI (adjusted OR=1.10, 95%CI 0.76-1.61, p=0.61). The risk of target-lesion
and target-vessel revascularization did not differ between the 3 groups, as did the risk
of definite or probable stent thrombosis. No differences were observed in terms of in-
stent LL and in-segment BR.
Conclusion: Patients with moderate/severe RI undergoing PCI with the unrestricted
use of DES have an increased risk of cardiac death and MI as compared to patients
with normal renal function during long-term follow-up. However, the efficacy of DES
is unaffected by renal function with similar rates of repeat revascularization and
angiographic outcomes regardless of renal impairment.
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The Effect Of Cilostazol On The Antiplatelet Efficacy Of Patients with
Moderate Renal Dysfunction: Post-hoc Analysis Of CILON-T (Influence of
CILostazol based triple antiplatelet therapy ON ischemic complication after
drug eluting stent implantation) Trial
Min-Ho Lee1, Jung-Won Suh2, Seung-Pyo Lee1, Kyung Woo Park1, Hae-Young Lee1,
Hyun-Jae Kang1, Bon-Kwon Koo1, Young-Seok Cho2, Tae-Jin Youn2, In-Ho Chae2,
Dong-Ju Choi2, Seung-Woon Rha3, Jang-Ho Bae4, Taek-Geun Kwon4, Jang-Whan
Bae5, Myeong-Chan Cho5, Hyo-Soo Kim1
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Republic of Korea; 5Chungbuk National University Hospital, Cheongju, Republic of
Korea
Background: Chronic renal failure is known as one of the risk factors which predict
poor response to clopidogrel. However, there are few data regarding patients with
moderately decreased glomerular filtration rate (GFR).
Methods: In the CILON-T trial, 915 consecutive patients who underwent drug-eluting
stent implantation were randomized to receive either dual (DAT) or triple antiplatelet
therapy (TAT). We calculated GFR at the index admission and classified patients
according to GFR (Group 1: GFR≥60mL/min/1.73m2; Group 2:
30mL/min/1.73m2≤GFR<60mL/min/1.73m2). We compared P2Y12 reaction unit
(PRU), P2Y12 % and interval change of GFR between the two groups at six moths
follow up.
Results: 184 patients (20.1%) showed renal dysfunction
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(30mL/min/1.73m2≤GFR<60mL/min/1.73m2) in the CILON-T trial. Patients with
decreased renal function were more anemic, diabetic and hypertensive. In addition,
they had more severe angina and previous history of percutaneous coronary
intervention. Baseline PRU and P2Y12 % inhibition did not different between two
groups. At six months follow-up, patients with renal dysfunction showed higher PRU
(330.4±57.2 vs. 312.4±66.3, p=0.005) and lower P2Y12 % inhibition (26.2±20.5% vs.
30.9±25.9%, p=0.029). In the subgroup analysis of patients with renal dysfunction,
patients treated with TAT (n=98) showed more platelet inhibition than those with DAT
(n=96) (PRU: 334.7±58.4 vs. 325.9±56.0, p=0.379; P2Y12 % inhibition: 30.5±20.4%
vs 21.8±19.8%, p=0.013). There were no differences in the interval change of GFR
between two groups (TAT: 52.2±7.2 vs. 53.5±12.1, p=0.071; DAT: 53.2±5.9 vs.
54.7±10.6, p=0.928; between two groups: p=0.376).
Conclusion: Patients with moderate renal dysfunction showed significantly lower
responsiveness to clopidogrel at six months. The treatment of cilostazol on top of
clopidogrel significantly improved the P2Y12 inhibition without deterioration of renal
function.
TCT-496
Objectives: The purpose of this study was to determine the functional impact of
cilostazol in patients with chronic kidney disease (CKD) undergoing
hemodialysis
Weon Kim1, Won-Yu Kang2, Jong-Shin Woo1
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Background: Impaired renal function is associated with reduced responsiveness to
clopidogrel. There is no study to overcome platelet hyporesponsiveness in CKD
patients. The purpose of this study was to determine the functional impact of cilostazol
in patients with chronic kidney disease (CKD) undergoing hemodialysis.
Methods: A total of 63 patients with CKD undergoing hemodialysis were enrolled.
Patients were randomly assigned to receive either a daily dose of 75 mg of clopidogrel
(group 1, n = 21) or a daily dose of 150 mg (group 2, n = 22) or a daily dose of 75 mg
of clopidogrel with 200mg of cilostazol (group 3; n = 20) for 14 days. Another 22
patients with normal renal function undergoing PCI were treated with 75 mg of
clopidogrel for control group. Platelet function and activation markers were assessed
before and after antiplatelet agents.
Results: Baseline platelet function measurements were similar in 3 groups. But CKD
group showed significantly higher platelet aggregation compared with control groups.
After 14 days, the maximal inhibition of platelet aggregation was 19.0 ± 9.8 % in the
group 1, 17.5 ± 9.9 % in the group 2, and 38.1 ± 14.4 % in the group 3 (p < 0.05). The
VerifyNowTM P2Y12 assay also indicated lower P2Y12 reaction units in group 3
(240.6 ± 59.6) than group 1 (317.9 ± 42.6) or group 2 (304.3 ± 67.3) (p < 0.01). The
rate of high on-treatment platelet reactivity was significantly lower in group 3 than in
1 and 2 groups (10% vs 43% vs 32%, respectively, p < 0.05). After treatment, the
changes of plasma sCD40L and sP-selectin levels were significantly higher in group 3
compared with group 1 and 2 (p < 0.01). But increase of the clopidogrel maintenance
dose from 75 to 150 mg did not show significant differences of platelet function and
activation markers.
Conclusion: Adjunctive cilostazol improves platelet inhibition as compared with
conventional or high maintenance dose of clopidogrel in patients with CKD undergoing
hemodialysis.
TCT-497
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
in Patients with Chronic Kidney Disease: A Report From the National Heart,
Lung, and Blood Institute Dynamic Registry
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David O Williams2, Sheryl F Kelsey1, Kevin E Kip1, Oscar C Marroquin1
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Background: Current guidelines suggest dual antiplatelet therapy (DAPT) for a
minimum of 12 months after PCI with a drug-eluting stent (DES). However, the
optimal duration of DAPT in patients with chronic kidney disease (CKD) remains
ambiguous given that these patients have an increased risk of both thrombotic and
bleeding events. Therefore, we sought to investigate the association between the
duration of DAPT and adverse cardiovascular events in patients with CKD who
received PCI.
Methods: 653 patients were selected from wave 4 (2004) and wave 5 (2006) of the
NHLBI Dynamic Registry who had an estimated glomerular filtration rate < 60ml/min.
A landmark analysis was performed on all patients who were event free at 12 months
after their index PCI with DES implantation, and they were stratified by whether they
were still on DAPT or not. All patients were followed for three years after that for the
occurrence of cardiovascular events.
Results: Of the 653 patients, 438 (67%) were on DAPT and 215 (33%) were not on
DAPT at 1 year. The mean age, prevalence of DM, HTN, and PAD were similar
between the two groups. Patients on DAPT at 1 year were more likely to have their
index PCI to treat a MI, but less likely to have had GI bleeds, prior strokes, and to be
on warfarin, as compared to those not on DAPT at one year. At 4 years from their index
PCI, patients who stayed on a longer duration of DAPT had a lower rate of death
(16.0% vs 23.9%, p=0.0086) than those on a shorter duration of DAPT (figure). There
were no differences in rates of MI (5.3% vs 5.0%, p=0.84), repeat revascularization
(10.7% vs 7.5%, p= 0.16), and stent thrombosis (0.6% vs 0.0%, p=0.33) between the
two groups.
Conclusion: Our data suggests that in this high-risk population of patients with CKD
who undergo PCI with DES, that longer duration of DAPT is safe and probably
beneficial in improving long-term outcomes.
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The Prognostic Value Of Admission Serum Creatinine for Contrast Induced
Nephropathy and 12 Months Mortality In Patients with Acute ST Elevation
Myocardial Infarction Underwent Primary Percutaneous Coronary
Intervention
Han-Young Jin1, Sang-Ryul Jung1, Jeong-Sook Seo1, Jae-Sik Jang1, Tae-Hyun Yang1,
Dae-Kyeong Kim1, Bomin Park2, Dong-Kie Kim2, Ki-Hun Kim2, Sang-Hoon Seol2,
Doo-Il Kim2, Dong-Soo Kim1, Sang-Ryul Chung1
1internal medicine, Inje University College of Medicine, Busan Paik Hospital,
Busan, Republic of Korea; 2Inje University College of Medicine, Haeundae Paik
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Background: Chronic kidney disease (CKD) is associated with increased risk of
adverse cardiovascular events, including contrast induced nephropathy (CIN) after
percutaneous coronary intervention (PCI). But, prognostic significance of admission
serum creatinine for CIN and mortality in patients with ST elevation myocardial
infarction (STEMI) is not known. So, the aim of this study was to evaluate impact of
admission serum creatinine on cardiovascular death and CIN in patients with STEMI
underwent primary PCI.
Methods: We analyzed 328 consecutive patients with STEMI underwent primary PCI.
The patients were divided into two groups according to admission serum creatinine
level; group I: ≤ 1.2mg/dl (n=244, 74.4%), group II: > 1.2 mg/dL (n=84, 25.6%).
Contrast-induced nephropathy was defined as an increase in serum creatinine level
>25% or 0.5 mg/dL after 48 hours. We sought CIN and cardiovascular death at 12-
month follow-up.
Results: Baseline clinical characteristics were similar between the two groups. Group
II was associated with a significantly higher rate of CIN (8.4% vs. 26.9%, p < 0.001)
and cardiovascular death (6.6% vs. 18.8%, p = 0.01) compared with group I. At 12-
month follow-up, the death-free survival rate was lower in the group II compared with
group I (p <0.001). Also, when each serum creatinine group was divided according to
presensce of CIN, 12-month death-free survival was signicantly different between four
groups (log rank test p < 0.001)(Figure).
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